Vaccine composition

Abstract

An intraorally administrable vaccine composition useful to be a preventive or therapeutic agent for infectious diseases, and effectively induces a systemic immune response or a mucosal immune response is provided. A vaccine composition for administration to the oral cavity of a human or an animal, the vaccine composition containing at least one antigen derived from an infectious disease, and at least one selected from the group consisting of a toll-like receptor 4 (TLR4) agonist, a toll-like receptor 2/6 (TLR2/6) agonist, and cyclic dinucleotide, or a derivative or salt thereof.

What is claimed is: 
     
         1 . A vaccine composition for administration to the oral cavity of a human or an animal, the vaccine composition comprising:
 at least one antigen derived from an infectious disease, and   at least one selected from the group consisting of: a toll-like receptor 4 (TLR4) agonist, a toll-like receptor 2/6 (TLR2/6) agonist, and cyclic dinucleotide, or a derivative or salt thereof,   wherein the antigen derived from an infectious disease is an inactivated whole influenza virus.   
     
     
         2 . The vaccine composition according to  claim 1 ,
 wherein the toll-like receptor 4 (TLR4) agonist comprises at least one selected from the group consisting of: lipopolysaccharide, or salt thereof, and monophosphoryl lipid, or salt thereof.   
     
     
         3 . The vaccine composition according to  claim 2 ,
 wherein the lipopolysaccharide, or salt thereof is derived from  Escherichia coli, Salmonella, Pantoea, Acetobacterium, Zymomonas, Xanthomonas  or  Enterobacter ; and   the monophosphoryl lipid, or salt thereof is monophosphoryl lipid derived from  Salmonella  or synthetic glucopyranosyl lipid.   
     
     
         4 . The vaccine composition according to  claim 1 , wherein the toll-like receptor 2/6 (TLR2/6) agonist comprises diacylated lipopeptide, or a derivative or salt thereof. 
     
     
         5 . The vaccine composition according to  claim 4 , wherein the diacylated lipopeptide comprises Pam 2 CSK 4 , MALP-2, FSL-1, or a derivative or salt thereof. 
     
     
         6 . The vaccine composition according to  claim 1 , wherein the cyclic dinucleotide comprises c-di-GMP, c-di-AMP, or a derivative or salt thereof. 
     
     
         7 . The vaccine composition according to  claim 3 , wherein the lipopolysaccharide, or salt thereof is derived from  Pantoea.    
     
     
         8 . The vaccine composition according to  claim 1 , wherein the vaccine composition induces a mucosal immune response and a systemic immune response,
 the mucosal immune response is antigen-specific IgA antibody production, and   the systemic immune response is antigen-specific IgG antibody production and antigen-specific cell-mediated immune production.